Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064704 | 1.00 | PDE10A (0.47) | PDE10ATP53P2RX7SMN1; SMN2MAPT | |
| SCHEMBL23065109 | 0.89 | SMN1; SMN2 (0.46) | TP53P2RX7SMN1; SMN2 | |
| SCHEMBL23065108 | 0.88 | TP53 (0.48) | TP53SMN1; SMN2 | |
| SCHEMBL23064700 | 0.86 | NPC1 (0.45) | — | |
| SCHEMBL24089999 | 0.85 | MAPT (0.50) | SMN1; SMN2MAPT | |
| SCHEMBL24089976 | 0.84 | TP53 (0.52) | TP53SMN1; SMN2MAPT | |
| SCHEMBL23064203 | 0.84 | TP53 (0.50) | PDE10ATP53 | |
| SCHEMBL29623109 | 0.84 | TP53 (0.50) | PDE10ATP53 | |
| SCHEMBL23064701 | 0.82 | PI4KA (0.46) | TP53P2RX7SMN1; SMN2MAPT | |
| SCHEMBL29623403 | 0.82 | PI4KA (0.46) | TP53P2RX7SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | claimed |
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | PDE10A 1456/4885TP53 3625/4885P2RX7 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.